Medical Oncologist
CION Cancer Clinics
Atezolizumab plus bevacizumab for liver cancer: who it is for | CION Cancer Clinics
Atezolizumab plus bevacizumab is an immunotherapy and a targeted drug given together for liver cancer that cannot be removed or treated locally. It is often the first drug treatment offered when the liver is still working well. This page explains what the team checks before offering it, what happens before the first drip, how it compares with tablets, and who it does not suit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is atezolizumab plus bevacizumab, and who is it for?
- What does the team look at before offering it?
- What happens before and during treatment?
- How does it compare with the other first options?
- Who does this combination not suit?
- What this page cannot tell you
- Common questions about atezolizumab plus bevacizumab
The short answer
What is atezolizumab plus bevacizumab, and who is it for?
Atezolizumab plus bevacizumab is a pair of drips given together for hepatocellular carcinoma (HCC), the cancer that starts in the liver cells themselves. It is used when the cancer cannot be removed, burned or treated through the blood vessels of the liver, and the liver itself is still working reasonably well.
Two medicines with two different jobs
Atezolizumab is an immunotherapy. It takes the brake off the immune system so it can recognise the cancer. Bevacizumab is a targeted therapy. It blocks a signal tumours use to grow new blood vessels. Large trials found that using both together worked better than the older tablet, sorafenib, for many people with advanced HCC. That is why guidelines now name it as a usual first option.
Which liver cancer this page is about
This page is about primary liver cancer. If your scan shows cancer that spread to the liver from the bowel, breast or elsewhere, the treatment follows the original cancer, and this combination is usually not the one used. For colorectal spread, see the colon cancer pages.
This is a decision page. How each drug works and its side effects are covered on the immunotherapy for liver cancer page.Before anyone says yes
What does the team look at before offering it?
The tumour board looks at three things together. A good answer on one does not make up for a poor answer on another.
The tumour
Is it too large, too many or too spread out for surgery, ablation or TACE? Has it grown into the portal vein, the main vein that carries blood into the liver, or spread outside the liver? These findings point towards a drug that travels through the whole body.
The liver
Most of the evidence comes from people whose liver function is graded Child-Pugh A, the best-working group. With weaker livers the benefit is less certain and the risks rise.
Checked with
- Bilirubin and albumin blood tests
- Clotting test (INR)
- Any fluid in the abdomen or confusion
You as a whole person
How active you are day to day, your heart, your blood pressure, your kidneys, and any autoimmune illness such as lupus or rheumatoid arthritis all shape whether this pair is safe for you.
Bleeding risk
Bevacizumab can make bleeding more likely. Swollen veins in the food pipe, called varices, are common in cirrhosis and must be looked for and treated first.
Not sure whether this applies to you?
Ask an oncologistFrom decision to first drip
What happens before and during treatment?
Scans and blood tests
A recent contrast CT or MRI, liver function tests, kidney tests, a thyroid check and hepatitis B and C tests. CION arranges the scans through diagnostic partners.
An endoscopy for varices
A camera test of the food pipe, arranged through a partner hepatologist or gastroenterologist. Large varices are banded or treated with medicine before bevacizumab starts. See why the endoscopy comes first.
Hepatitis B brought under control
If you carry hepatitis B, antiviral tablets are started or continued so the virus does not flare during immunotherapy.
The drips themselves
Both drugs are given into a vein at a CION centre on the same day, then repeated on a regular plan your oncologist explains. Blood tests and a blood pressure check come before each visit, and scans are repeated to see whether the cancer is responding.
Side by side
How does it compare with the other first options?
Atezolizumab plus bevacizumab
The usual alternatives
Drips given at a centre
Sorafenib and lenvatinib are tablets taken at home
Needs varices checked and treated first
Durvalumab plus tremelimumab carries no bevacizumab bleeding concern
Not safe after a liver transplant
Tablets are often the choice after a transplant
Immune side effects, such as thyroid or liver inflammation
Tablets bring hand-foot skin soreness, diarrhoea and tiredness
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Not for everyone
Who does this combination not suit?
It is a strong first option, and it is still wrong for a fair number of people. Your oncologist will usually steer away from it if any of these apply to you.
Reasons it is usually avoided
- A liver transplant in the past, because immunotherapy can trigger rejection of the new liver
- Varices that have bled recently, or large varices that have not yet been treated
- An active autoimmune disease, or an organ transplant of any kind
- Poorly controlled blood pressure, a recent heart attack or stroke, or a recent blood clot
- Liver function graded Child-Pugh C, or yellowing and fluid that are getting worse
- A recent operation or a wound that has not yet healed
Where the answer is less clear
People with Child-Pugh B livers were largely left out of the main trials. Some are offered it after careful discussion, and others do better with a tablet or with comfort-focused care. The full list is on who cannot have atezolizumab plus bevacizumab.
Being straight with you
What this page cannot tell you
It cannot tell you whether this combination is right for you, or how well it will work in your case. Some people see their tumours shrink, some see them hold steady, and some find the cancer keeps growing. Nobody can say in advance which group you will be in, and no figure on a website describes one person.
It cannot price your treatment
Costs depend on the brand or biosimilar used, your weight, how long treatment continues and what your insurance or scheme covers. Ask for a written, itemised estimate once a plan is agreed.
Who can answer these questions
A medical oncologist who has seen your scans, your blood results and your endoscopy report, working with a hepatologist. At CION the case is discussed at a tumour board before a plan is confirmed. Bring every report you have, including old scans from your district hospital.
Questions we are asked
Common questions about atezolizumab plus bevacizumab
Is atezolizumab plus bevacizumab available in India?
Yes. Atezolizumab is approved in India, and bevacizumab is available both as the original brand and as several biosimilars. Supply and brand choice can vary between hospitals and pharmacies, so your team will confirm which versions they use and whether your insurer or scheme recognises them.
Is this chemotherapy?
No. Atezolizumab is an immunotherapy and bevacizumab is a targeted therapy. Neither works like the older chemotherapy drugs, which have a limited role in liver cancer. Hair loss and heavy vomiting are not typical. The side effects are different, and your team will explain which ones to watch for.
Can I have it if I have cirrhosis?
Often, yes. Most people in the trials had cirrhosis. What matters is how well the liver is working, graded by Child-Pugh, and whether varices have been checked and treated. A well-working cirrhotic liver is usually acceptable. A failing one usually is not.
I have hepatitis B. Is it still possible?
Usually, yes, once the virus is controlled with antiviral tablets. Hepatitis B is controlled, not removed, so the tablets are normally continued throughout treatment. Your oncologist and a hepatologist will plan this together. Do not stop antiviral tablets on your own.
Why do I need an endoscopy first?
Bevacizumab raises the chance of bleeding. Many people with cirrhosis have swollen veins in the food pipe that can bleed. An endoscopy finds them, and banding or medicine makes them safer before treatment starts. Skipping it puts you at real risk.
How long does treatment go on?
Usually for as long as it keeps the cancer under control and the side effects are manageable. Scans are repeated at intervals to check. If one drug causes trouble, the other is sometimes continued alone. Your oncologist will explain the plan for your case.
What happens if it stops working?
There are other options, usually tablets such as lenvatinib or sorafenib, or later drugs such as cabozantinib. Whether they suit you depends on your liver and your strength at that point. Read second-line treatment after first-line fails.
Can I get a second opinion at CION on a plan I was given?
Yes. Bring your scans, blood reports, endoscopy report and the written plan. A CION medical oncologist will review them and the tumour board can discuss the case. Call the helpline and someone will tell you which reports to bring.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- National Cancer Institute — Liver Cancer Treatment
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Why atezolizumab plus bevacizumab is usually first choiceThe reasoning behind the guideline preferenceWho cannot have atezolizumab plus bevacizumabThe full list of reasons it may be ruled outDurvalumab plus tremelimumab for liver cancerThe main immunotherapy alternativeWhy you need an endoscopy before bevacizumabThe safety check that comes before the first drip
Talk to us
Has your doctor suggested atezolizumab plus bevacizumab?
Send us your scans, blood reports and the plan you were given, and a medical oncologist will go through them with you. One helpline serves every CION centre.